This page is an educational summary and does not constitute clinical guidance or a recommendation for use. Prescribing, dosing and treatment decisions should be made on the basis of individual patient assessment, current clinical guidelines and the treating healthcare professional's judgement.
What is CBDA?
CBDA (C₂₂H₃₀O₄) is a naturally occurring cannabinoid in Cannabis sativa. CBDA is the primary cannabinoid in raw CBD-dominant cannabis — directly biosynthesised from CBGA. Converts to CBD by decarboxylation. Incoming material for CBD manufacturing is predominantly CBDA.
Pharmacology
Potent 5-HT1A agonist (reportedly more potent than CBD for this receptor), FAAH inhibition (increases endocannabinoid anandamide). Anti-nausea effects in animal models that appear more potent than CBD.
Current Evidence
GW Pharmaceuticals investigated CBDA as EPM301 for nausea. Preclinical evidence demonstrates potent anti-nausea effects. A key finding: CBDA appears significantly more potent than CBD in 5-HT1A-mediated effects, suggesting undecarboxylated preparations may have distinct clinical effects.
GMP Relevance
CBDA is the dominant cannabinoid in CBD cannabis starting material before processing. Specifications should include CBDA as primary cannabinoid assay parameter with conversion factor to CBD potential (CBDA × 0.877). Decarboxylation CBDA→CBD must be formally validated under EU GMP Annex 15.
Regulatory Status
CBDA is not independently scheduled as a controlled substance in most European jurisdictions as a component of cannabis starting material. Pharmaceutical preparations require EU GMP manufacturing standards. Specifications should include identity, purity and assay by validated HPLC.
See the Cannabis Glossary for definitions of related cultivation, extraction and quality terms.
References
- Bolognini D et al. Cannabidiolic acid prevents vomiting via 5-HT1A enhancement. Br J Pharmacol. 2013.
- Rock EM, Parker LA. Cannabinoids for Chemotherapy-Induced Nausea. Front Pharmacol. 2016.